FDA Bolsters Post-Market Scrutiny Of Drugs
The U.S. Food and Drug Administration has beefed up its scrutiny of drugs after they are initially approved, including issuing more advisories on drug safety issues, as well as requiring more...To view the full article, register now.
Already a subscriber? Click here to view full article